Page 190 - Read Online

Gim et al. Hepatoma Res 2023;9:51 https://dx.doi.org/10.20517/2394-5079.2023.90 Page 19 of 20

73. Chen C, Di Bartolomeo M, Corallo S, Strickler JH, Goyal L. Overcoming resistance to targeted therapies in gastrointestinal cancers:
progress to date and progress to come. Am Soc Clin Oncol Educ Book 2020;40:161-73. DOI PubMed
74. Kwak EL, Ahronian LG, Siravegna G, et al. Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy
in MET-amplified esophagogastric cancer. Cancer Discov 2015;5:1271-81. DOI PubMed PMC
75. Pietrantonio F, Caporale M, Morano F, et al. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab
therapy: Implication for further clinical research. Int J Cancer 2016;139:2859-64. DOI PubMed
76. Seo S, Ryu MH, Park YS, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients:
results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer 2019;22:527-35. DOI
77. Harding JJ, Piha-Paul SA, Shah RH, et al. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract
cancers. Nat Commun 2023;14:630. DOI PubMed PMC
78. Vikis HG, Clark O, Furegato M, et al. Mapping the epidemiologic characteristics of cancer patients with NTRK gene fusions: a real-
world analysis of the cerner enviza eletronic health records (EHR) database. JCO 2022;40:e15123. DOI
79. U.S. Food & Drug Administration. FDA Approves larotrectinib for solid tumors with NTRK gene fusions. Available from: https://
www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions [Last accessed on 25 Dec 2023].
80. U.S. Food & Drug Administration. FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC. Available from: https://
www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc [Last accessed
on 25 Dec 2023].
81. Drilon AE, Hong DS, van Tilburg CM, et al. Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with
tropomyosin receptor kinase (TRK) fusion cancer. JCO 2022;40:3100. DOI
82. Doebele RC, Drilon A, Paz-Ares L, et al; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive
solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271-82. DOI PubMed PMC
83. Krzakowski MJ, Lu S, Cousin S, et al. Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally
advanced/metastatic NTRK fusion-positive ( NTRK -fp) solid tumors. JCO 2022;40:3099. DOI
84. Kojadinovic A, Laderian B, Mundi PS. Targeting TRK: A fast-tracked application of precision oncology and future directions. Crit
Rev Oncol Hematol 2021;165:103451. DOI PubMed
85. Harada G, Choudhury NJ, Schram AM, et al. Mechanisms of acquired resistance to TRK inhibitors. JCO 2022;40:3104. DOI
86. Katayama R, Gong B, Togashi N, et al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib
resistant ROS1-G2032R mutation in preclinical models. Nat Commun 2019;10:3604. DOI PubMed PMC
87. Paratala BS, Chung JH, Williams CB, et al. RET rearrangements are actionable alterations in breast cancer. Nat Commun
2018;9:4821. DOI PubMed PMC
88. Drusbosky LM, Rodriguez E, Dawar R, Ikpeazu CV. Therapeutic strategies in RET gene rearranged non-small cell lung cancer. J
Hematol Oncol 2021;14:50. DOI PubMed PMC
89. Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. RET aberrations in diverse cancers: next-generation sequencing of
4,871 patients. Clin Cancer Res 2017;23:1988-97. DOI PubMed
90. Subbiah V, Cassier PA, Siena S, et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the
phase 1/2 ARROW trial. Nat Med 2022;28:1640-5. DOI PubMed PMC
91. FDA approves pralsetinib for lung cancer with RET gene fusions. Available from: https://www.fda.gov/drugs/resources-information-
approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions [Last accessed on 25 Dec 2023].
92. FDA approves pralsetinib for RET-altered thyroid cancers. Available from: https://www.fda.gov/drugs/resources-information-
approved-drugs/fda-approves-pralsetinib-ret-altered-thyroid-cancers#:~:text=On%20December%201%2C%202020%2C%
20the,fusion%2Dpositive%20thyroid%20cancer%20who [Last accessed on 25 Dec 2023].
93. FDA D.I.S.C.O. Burst Edition: FDA approvals of Retevmo (selpercatinib) for adult patients with locally advanced or metastatic RET
fusion-positive solid tumors, and Retevmo (selpercatinib) for adult patients with locally advanced or metastatic RET fusion-positive
non-small cell lung cancer. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-
edition-fda-approvals-retevmo-selpercatinib-adult-patients-locally-advanced-or#:~:text=On%20September%2021%2C%202022%
2C%20the,who%20have%20no%20satisfactory%20alternative [Last accessed on 25 Dec 2023].
94. Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid
tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol 2022;23:1261-73.
DOI PubMed
95. Santoro M, Moccia M, Federico G, Carlomagno F. RET gene fusions in malignancies of the thyroid and other tissues. Genes
2020;11:424. DOI PubMed PMC
96. Andrini E, Mosca M, Galvani L, et al. Non-small-cell lung cancer: how to manage RET-positive disease. Drugs Context 2022;11:1-
12. DOI PubMed PMC
97. Rosen EY, Won HH, Zheng Y, et al. The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. Nat Commun
2022;13:1450. DOI PubMed PMC
98. Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell 2019;76:359-70. DOI
PubMed PMC
99. Riaz N, Havel JJ, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell
2017;171:934-49.e16. DOI PubMed PMC